Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibitors, sodium and off-target effects: an overview
Antonio De Pascalis, Giuseppe Cianciolo, Irene Capelli, et al.
Journal of Nephrology (2020) Vol. 34, Iss. 3, pp. 673-680
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Metabolic Communication by SGLT2 Inhibition
A. Billing, Young Chul Kim, Søren Gullaksen, et al.
Circulation (2023) Vol. 149, Iss. 11, pp. 860-884
Open Access | Times Cited: 57
Recent Advances in Diabetic Kidney Diseases: From Kidney Injury to Kidney Fibrosis
Peir‐Haur Hung, Yung‐Chien Hsu, Tsung‐Hsien Chen, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11857-11857
Open Access | Times Cited: 93
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 35
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
Mengyuan Ge, Judith Molina, Jin‐Ju Kim, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 32
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
Marvin Heimke, Florian Lenz, Uta Rickert, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3107-3107
Open Access | Times Cited: 31
The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
Rujie Zheng, Wenjuan Song, Jie Lu, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
The diabetes medication Canagliflozin attenuates alcoholic liver disease by reducing hepatic lipid accumulation via SIRT1-AMPK-mTORC1 signaling pathway
Lei Chen, Qinhui Liu, Xiangyu Li, et al.
European Journal of Pharmacology (2025) Vol. 992, pp. 177320-177320
Closed Access
Magnitude and determinants of isolated systolic hypertension among type 2 diabetes patients in selected referral hospitals in Amhara Region, Ethiopia
Deresse Sinamaw Asmare, Temesgen Agegnehu Abebe, Mezgebu Miskir, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review
Lingli Xie, Wenfang Xia
Life Sciences (2022) Vol. 300, pp. 120543-120543
Closed Access | Times Cited: 21
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Neda Shakour, Shima Karami, Mehrdad Iranshahi, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 18, Iss. 1, pp. 102934-102934
Closed Access | Times Cited: 11
Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction
Kyung‐Duk Min, Yuki Matsumoto, Masanori Asakura, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 6, pp. 3470-3487
Open Access | Times Cited: 2
Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice
Peiyang Song, Tianyi Chen, Shunli Rui, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 12
Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
O. González-Albarrán, Cristóbal Morales, Manuel Pérez-Maraver, et al.
Diabetes Therapy (2022) Vol. 13, Iss. S1, pp. 35-49
Open Access | Times Cited: 11
Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions
Karanveer Singh Matharu, Kiran Chana, Charles J. Ferro, et al.
Pharmacology Research & Perspectives (2021) Vol. 9, Iss. 5
Open Access | Times Cited: 15
Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die
Ven Gee Lim, Hejie He, Thomas Lachlan, et al.
EP Europace (2021) Vol. 24, Iss. 7, pp. 1052-1057
Closed Access | Times Cited: 15
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
Luxi Ji, Mudit Mishra, Bart De Geest
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1092-1092
Open Access | Times Cited: 4
Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors
Tilman B. Drüeke, Ziad A. Massy
Kidney International (2024) Vol. 106, Iss. 1, pp. 12-15
Closed Access | Times Cited: 1
NQO1 Deficiency Aggravates Renal Injury by Dysregulating Vps34/ATG14L Complex during Autophagy Initiation in Diabetic Nephropathy
Geum-Lan Hong, Kyung‐Hyun Kim, Chul‐Ho Lee, et al.
Antioxidants (2021) Vol. 10, Iss. 2, pp. 333-333
Open Access | Times Cited: 10
Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes
Ding Li, Shang Liu, Hao Yan, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 11, pp. 1581-1587
Closed Access | Times Cited: 3
Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor
Benjamin Chin‐Yee, Anargyros Xenocostas
Annals of Hematology (2022) Vol. 101, Iss. 6, pp. 1373-1374
Closed Access | Times Cited: 4
Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura
Verónica González, Dra Verónica González, Doença Renal, et al.
Revista Uruguaya de Cardiología (2021) Vol. 36, Iss. 1
Open Access | Times Cited: 4
Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial
Hao Yan, Wei Wang, Ying Li, et al.
BMJ Open (2024) Vol. 14, Iss. 8, pp. e087617-e087617
Open Access
Cardiovascular and Renal Diseases in Type 2 Diabetes
Mukesh Nandave
(2024), pp. 151-247
Closed Access
Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
Takuya Oyakawa, Keita Miura, Nao Muraoka, et al.
Thoracic Cancer (2024)
Open Access
Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?
Despina Sanoudou, Christos S. Mantzoros, Michael A. Hill
Metabolism (2022) Vol. 137, pp. 155309-155309
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top